sp-102
Radiculopathy
Semnur Pharmaceuticals, Inc.UNKNOWNPhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Radiculopathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Kenacort University of Miami | Phase 4 | BBB |
Lidocaine Sheba Medical Center | Phase 4 | BBB |
Dexasone Semnur Pharmaceuticals, Inc. | Phase 4 | BB |
Celestone Sheba Medical Center | Phase 4 | BB |
Artemin Biogen | Phase 2 | BB |
View all 35 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →